Lv5
810 积分 2024-02-07 加入
EVOLVE platform, a trispecific T cell engager with integrated CD2 costimulation, for the treatment of solid and hematologic tumors
1个月前
已完结
Linker Chemistry in Antibody–Drug Conjugates: Current Strategies, Clinical Pharmacokinetic Analyses, and Linker-Free Outlooks
1个月前
已完结
Targeting TROP2 in drug-tolerant persister cells delays EGFR tyrosine kinase inhibitor resistance in non-small-cell lung cancer
1个月前
已完结
TROP-2-targeted antibody-drug conjugate SHR-A1921 for advanced or metastatic solid tumors: A first-in-human phase 1 study
1个月前
已完结
Overcoming ADC resistance in advanced colorectal cancer by dual targeting of TROP2 and PERK to suppress Wnt/β-catenin signaling
1个月前
已完结
TROP2 targeting reveals therapy-driven cell state dynamics in colorectal cancer
1个月前
已完结
TROP-2 in solid tumors: From oncogenic driver to therapeutic target with antibody-drug conjugates
1个月前
已完结
Navigating the clinical progress of antibody-drug conjugates: Emerging opportunities and remaining challenges
2个月前
已完结
Mechanisms of resistance to antibody–drug conjugates in cancers
2个月前
已完结
Unveiling the molecular and immunological drivers of antibody–drug conjugates in cancer treatment
2个月前
已完结
皖公网安备34019202002308
